Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.

van der Straten A, Van Damme L, Haberer JE, Bangsberg DR.

AIDS. 2012 Apr 24;26(7):F13-9. doi: 10.1097/QAD.0b013e3283522272.

PMID:
22333749
2.

Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C; Partners PrEP Study Team..

Lancet Infect Dis. 2014 Nov;14(11):1055-64. doi: 10.1016/S1473-3099(14)70937-5.

3.

Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.

Plosker GL.

Drugs. 2013 Mar;73(3):279-91. doi: 10.1007/s40265-013-0024-4. Review.

PMID:
23444256
4.

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.

Okwundu CI, Uthman OA, Okoromah CA.

Cochrane Database Syst Rev. 2012 Jul 11;(7):CD007189. doi: 10.1002/14651858.CD007189.pub3. Review.

PMID:
22786505
5.

FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.

Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, Lombaard J, Manongi R, Kapiga S, Kashuba A, Van Damme L; FEM-PrEP Study Group..

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):324-31. doi: 10.1097/QAI.0000000000000158.

6.

Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.

Celum C, Baeten JM.

Curr Opin Infect Dis. 2012 Feb;25(1):51-7. doi: 10.1097/QCO.0b013e32834ef5ef. Review.

7.

Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.

Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM; Partners PrEP Study Team..

JAMA. 2014 Jul 23-30;312(4):362-71. doi: 10.1001/jama.2014.8735.

8.

Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.

Myers GM, Mayer KH.

AIDS Patient Care STDS. 2011 Feb;25(2):63-71. doi: 10.1089/apc.2010.0222. Review.

PMID:
21284497
9.

Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.

Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM; Partners PrEP Study Team..

Ann Intern Med. 2014 Jul 1;161(1):11-9. doi: 10.7326/M13-2471.

PMID:
24979446
10.

HIV preexposure prophylaxis: new data and potential use.

Celum CL.

Top Antivir Med. 2011 Dec;19(5):181-5.

11.

Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, Kiarie J, Ronald A, Baeten JM; Partners PrEP Study Team..

JAMA Intern Med. 2015 Feb;175(2):246-54. doi: 10.1001/jamainternmed.2014.6786.

12.

Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa.

Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, Safren SA, Ware NC, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR.

PLoS Med. 2013;10(9):e1001511. doi: 10.1371/journal.pmed.1001511.

13.

Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.

Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, Bangsberg DR, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Kamali A, Priddy FH.

PLoS One. 2013 Sep 26;8(9):e74314. doi: 10.1371/journal.pone.0074314.

14.

HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.

Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8. doi: 10.1097/QAI.0000000000000172.

15.

Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.

Donnell D, Hughes JP, Wang L, Chen YQ, Fleming TR.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S130-4. doi: 10.1097/QAI.0b013e3182986fac.

16.

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.

Hendrix CW, Chen BA, Guddera V, Hoesley C, Justman J, Nakabiito C, Salata R, Soto-Torres L, Patterson K, Minnis AM, Gandham S, Gomez K, Richardson BA, Bumpus NN.

PLoS One. 2013;8(1):e55013. doi: 10.1371/journal.pone.0055013.

17.

Pre-exposure chemoprophylaxis of HIV infection: quo vadis?

Clercq ED.

Biochem Pharmacol. 2012 Mar 1;83(5):567-73. doi: 10.1016/j.bcp.2011.10.016.

PMID:
22067069
18.

Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis.

Lehman DA, Baeten JM, McCoy CO, Weis JF, Peterson D, Mbara G, Donnell D, Thomas KK, Hendrix CW, Marzinke MA, Frenkel L, Ndase P, Mugo NR, Celum C, Overbaugh J, Matsen FA; Partners PrEP Study Team..

J Infect Dis. 2015 Apr 15;211(8):1211-8. doi: 10.1093/infdis/jiu677.

19.

Preexposure prophylaxis for HIV prevention: where have we been and where are we going?

Baeten JM, Haberer JE, Liu AY, Sista N.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S122-9. doi: 10.1097/QAI.0b013e3182986f69. Review.

20.

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.

Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, Cohen MS, Kashuba AD.

Sci Transl Med. 2011 Dec 7;3(112):112re4. doi: 10.1126/scitranslmed.3003174.

Items per page

Supplemental Content

Support Center